Long-term outcome of hepatitis C infection after liver transplantation
- PMID: 8596547
- DOI: 10.1056/NEJM199603283341302
Long-term outcome of hepatitis C infection after liver transplantation
Abstract
Background: End-stage cirrhosis related to hepatitic C virus (HCV) is a common reason for liver transplantation, although viremia ia known to persist in most cases. We investigated the impact of persistent HCV infection after liver transplantation on patient and graft survival and the effects of the HCV genotype and the degree of HLA matching between donor and recipient on the severity of recurrent hepatitis.
Methods: A group of 149 patients with HCV infection who received liver transplants between January 1982 and April 1994 were followed for a median of 36 months; 623 patients without HCV infection who underwent liver transplantation for end-stage chronic liver disease were used as a control group. A total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens were obtained from 91 of the HCV-negative patients five years after transplantation.
Results: Cumulative survival rates for the 149 patients with HCV infection were 79 percent after one year, 74 percent after three years, and 70 percent after five years, as compared with rates of 75 percent, 71 percent, and 69 percent, respectively, in the HCV-negative transplant recipients (P=0.12). Of the 130 patients with hepatitis C infection who survived more than 6 months after transplantation, 15 (12 percent) had no evidence of chronic hepatitis on their most recent liver biopsy (median followup, 20 months), 70 (54 percent) had mild chronic hepatitis (median, 35 months), 35 (27 percent) had moderate chronic hepatitis (median, 35 months), and 10 (8 percent) had cirrhosis (median, 51 months). Graft loss occurred after a median of 303 days in 27 of the 149 patients, including 5 with HCV-related cirrhosis and 3 with HCV-related cholestatic hepatitis. Infection with HCV genotype 1b was associated with more severe graft injury, whereas the primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients had no significant effect on this variable.
Conclusions: After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. After five years, the rates of graft and overall survival are similar between patients with and those without HCV infection.
Comment in
-
Long-term outcome of hepatitis C infection after liver transplantation.N Engl J Med. 1996 Aug 15;335(7):522; author reply 522-3. doi: 10.1056/NEJM199608153350716. N Engl J Med. 1996. PMID: 8676962 No abstract available.
-
Long-term outcome of hepatitis C infection after liver transplantation.N Engl J Med. 1996 Aug 15;335(7):522; author reply 522-3. N Engl J Med. 1996. PMID: 8676963 No abstract available.
Similar articles
-
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.Hepatology. 1999 Jan;29(1):250-6. doi: 10.1002/hep.510290122. Hepatology. 1999. PMID: 9862874 Clinical Trial.
-
Histological and clinical outcome after liver transplantation for hepatitis C.Hepatology. 1997 Dec;26(6):1646-52. doi: 10.1002/hep.510260638. Hepatology. 1997. PMID: 9398011
-
Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.Liver Transpl Surg. 1999 Jul;5(4):294-300. doi: 10.1002/lt.500050417. Liver Transpl Surg. 1999. PMID: 10388502
-
Hepatitis C virus infection and renal transplantation.Am J Kidney Dis. 2001 Nov;38(5):919-34. doi: 10.1053/ajkd.2001.28576. Am J Kidney Dis. 2001. PMID: 11684543 Review.
-
Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression.Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):445-58. doi: 10.1586/egh.10.39. Expert Rev Gastroenterol Hepatol. 2010. PMID: 20678018 Review.
Cited by
-
The prediction of immunological dysfunction during antiviral therapy for HCV after liver transplantation: can we improve outcomes?Hepatol Int. 2013 Oct;7(4):948-50. doi: 10.1007/s12072-013-9474-8. Epub 2013 Oct 17. Hepatol Int. 2013. PMID: 26202024 No abstract available.
-
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.Liver Int. 2013 Jan;33(1):72-8. doi: 10.1111/liv.12013. Epub 2012 Oct 29. Liver Int. 2013. PMID: 23107586 Free PMC article.
-
Racial differences in fibrosis progression after HCV-related liver transplantation.Transplantation. 2012 Jul 27;94(2):178-84. doi: 10.1097/TP.0b013e318253f7fa. Transplantation. 2012. PMID: 22743546 Free PMC article.
-
Effect of nonviral factors on hepatitis C recurrence after liver transplantation.Ann Surg. 2006 Oct;244(4):563-71. doi: 10.1097/01.sla.0000237648.90600.e9. Ann Surg. 2006. PMID: 16998365 Free PMC article.
-
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10. Clin Mol Hepatol. 2018. PMID: 30092624 Free PMC article. Review. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous